Studiencode:
| Institution: | IQVIA Commercial GmbH & Co. OHG | Auftraggeber: | GlaxoSmithKline |
| Titel der NIS: | Retrospective cohort of relapsing/refractory multiple myeloma (RRMM) patients, treated in terms of clinical practice, who have received at least three prior lines of anti-myeloma therapy to be compared with patients enrolled in GSK’s clinical trial NCT03525678 of GSK2857916 medicine (BCMA) in France, Germany, Italy, Spain, and the UK. | ||
| Ziel der NIS: | The purpose of this study was to provide an external control arm to the trial NCT03525678 (the GSK study 205678; DREAMM 2). Therefore, the overall objective was to generate a historical cohort of patients treated by RRMM treatments according to the local SoC, with nearly identical clinical characteristics as the trial population in France, Germany, Italy, Spain, and the UK. |
||
| Ort der Durchführung: | multinational | NIS angefordert: | nein |
| Patientenanzahl insgesamt: | 104 | Anzahl Ärzte insgesamt: | 12 |
| Patientenanzahl in Deutschland: | 51 | Ärzte in Deutschland: | 2 |
| Anzeige am: | 01.08.2019 | Geplanter Beginn: | 01.08.2019 | Geplantes Ende: | 15.07.2021 |
| Angezeigtes Ende der NIS am: 02.09.2021 | |||||
